{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:59:03Z","timestamp":1785369543308,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.005","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:20:43Z","timestamp":1779135643000},"page":"515-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes"],"prefix":"10.1016","volume":"55","author":[{"given":"Halis K.","family":"Akturk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ecl.2026.04.005_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","article-title":"Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes","volume":"15","author":"Laffel","year":"1999","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.005_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MED.0000000000000423","article-title":"SGLT inhibition: a possible adjunctive treatment for type 1 diabetes","volume":"25","author":"Akturk","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"S2","key":"10.1016\/j.ecl.2026.04.005_bib3","first-page":"S224","article-title":"Possible ways to improve postprandial glucose control in type 1 diabetes","volume":"20","author":"Akturk","year":"2018","journal-title":"Diabetes Technol Therapeut"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.005_bib4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1089\/dia.2023.0320","article-title":"Longitudinal trends in glycemic outcomes and technology use for over 48,000 people with type 1 diabetes (2016-2022) from the T1D exchange quality improvement collaborative","volume":"25","author":"Ebekozien","year":"2023","journal-title":"Diabetes Technol Therapeut"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.005_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/19322968211042656","article-title":"Continuous ketone monitoring consensus report 2021","volume":"16","author":"Nguyen","year":"2022","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.005_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.005_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.005_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ecl.2010.05.011","article-title":"Epidemiology of type 1 diabetes","volume":"39","author":"Maahs","year":"2010","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MED.0000000000000841","article-title":"Treating obesity in type 1 diabetes mellitus - review of efficacy and safety","volume":"31","author":"Freeby","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"19","key":"10.1016\/j.ecl.2026.04.005_bib10","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/jama.2024.18581","article-title":"GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes","volume":"332","author":"Li","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.005_bib11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.005_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.005_bib13","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-Week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.005_bib14","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.005_bib15","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"S4","key":"10.1016\/j.ecl.2026.04.005_bib16","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1177\/15209156251390828","article-title":"Global burden of diabetic ketoacidosis","volume":"27","author":"Mohan","year":"2025","journal-title":"Diabetes Technol Therapeut"},{"issue":"S4","key":"10.1016\/j.ecl.2026.04.005_bib17","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1177\/15209156251390832","article-title":"Economic impact of diabetic ketoacidosis in the United States","volume":"27","author":"Panjwani","year":"2025","journal-title":"Diabetes Technol Therapeut"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.005_bib18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2337\/dci24-0032","article-title":"Hyperglycemic crises in adults with diabetes: a consensus report","volume":"47","author":"Umpierrez","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.005_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.005_bib20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.diabet.2018.06.005","article-title":"SGLT2 inhibition and glucagon secretion in humans","volume":"44","author":"Saponaro","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ecl.2026.04.005_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.005_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12933-024-02539-x","article-title":"SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives","volume":"23","author":"Morciano","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"13","key":"10.1016\/j.ecl.2026.04.005_bib23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/0113816128289350240320063045","article-title":"Cellular and mitochondrial pathways contribute to SGLT2 inhibitors-mediated tissue protection: experimental and clinical data","volume":"30","author":"Sanz","year":"2024","journal-title":"Curr Pharm Des"},{"issue":"S4","key":"10.1016\/j.ecl.2026.04.005_bib24","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1177\/15209156251390818","article-title":"Clinical trials in diabetes: examining the value of use of continuous dual glucose-ketone monitoring","volume":"27","author":"Akturk","year":"2025","journal-title":"Diabetes Technol Therapeut"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.005_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.108030","article-title":"Accuracy of a breath ketone analyzer to detect ketosis in adults and children with type 1 diabetes","volume":"35","author":"Akturk","year":"2021","journal-title":"J Diabet Complicat"},{"issue":"S4","key":"10.1016\/j.ecl.2026.04.005_bib26","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1177\/15209156251392900","article-title":"Integrating continuous dual glucose-ketone monitoring into clinical practice","volume":"27","author":"Miller","year":"2025","journal-title":"Diabetes Technol Therapeut"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.005_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S2213-8587(25)00331-6","article-title":"Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology","volume":"14","author":"Dhatariya","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"S4","key":"10.1016\/j.ecl.2026.04.005_bib28","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1177\/15209156251390820","article-title":"Continuous dual glucose-ketone sensing technology","volume":"27","author":"Hoss","year":"2025","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2026.04.005_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/15209156261428034","article-title":"Continuous ketone monitoring in diabetic ketoacidosis: prospective multicenter method-comparison and feasibility study","author":"Haas","year":"2026","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.005_bib30","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2337\/dc23-0840","article-title":"Point-of-Care capillary blood ketone measurements and the prediction of future ketoacidosis risk in type 1 diabetes","volume":"46","author":"Song","year":"2023","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.005_bib31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/dia.2018.0246","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Therapeut"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.005_bib32","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"S3","key":"10.1016\/j.ecl.2026.04.005_bib33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1089\/dia.2017.2499","article-title":"The future of continuous glucose monitoring","volume":"19","author":"Garg","year":"2017","journal-title":"Diabetes Technol Therapeut"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.005_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MED.0000000000000467","article-title":"Technological advances shaping diabetes care","volume":"26","author":"Akturk","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10-b Suppl","key":"10.1016\/j.ecl.2026.04.005_bib35","first-page":"S7","article-title":"Advances in diabetes technology within the digital diabetes ecosystem","volume":"30","author":"Akturk","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ecl.2026.04.005_bib36","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.2147\/DMSO.S580423","article-title":"Revolutionizing diabetes care: from tech to therapeutics","volume":"18","author":"Akturk","year":"2025","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:24:34Z","timestamp":1785367474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000265"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.005","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}